

WE CLAIM:

1           1.       A unit dosage form for the treatment of herpes simplex and  
2 conditions giving rise thereto, said unit dosage form comprising as active ingredients:  
3           (a) a thiol-containing glutathione-increasing agent,  
4           (b) an L-lysine-increasing agent,  
5           (c) a glucosamine-increasing agent, and  
6           (d) magnesium.

1           2.       A unit dosage form in accordance with claim 1 in which said active  
2 ingredients are formulated as a substantially homogeneous tablet that releases all of said  
3 active ingredients into the stomach upon ingestion for contact with gastric fluid.

1           3.       A unit dosage form in accordance with claim 1 in which:  
2           (a) said thiol-containing glutathione-increasing agent is N-acetyl-  
3 L-cysteine,  
4           (b) said L-lysine-increasing agent is L-lysine monohydrochloride,  
5           (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose, and  
6           (d) said magnesium is in the form of magnesium ascorbate.

1           4.       A unit dosage form in accordance with claim 1 in which:  
2           (a) said thiol-containing glutathione-increasing agent is N-acetyl-  
3 L-cysteine in an amount ranging from about 80 mg to about 4000 mg,  
4           (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an  
5 amount ranging from about 150 mg to about 5000 mg,  
6           (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in  
7 an amount ranging from about 75 mg to about 2500 mg, and  
8           (d) said magnesium is in the form of magnesium ascorbate in an amount  
9 ranging from about 80 mg to about 3300 mg.

1           5.       A unit dosage form in accordance with claim 4 in which said active  
2 ingredients are formulated as a substantially homogeneous tablet that releases all of said  
3 active ingredients into the stomach upon ingestion for contact with gastric fluid.

1           6.       A unit dosage form in accordance with claim 5 further comprising  
2 as an active ingredient quercetin in an amount ranging from about 6 mg to about 300 mg.

1                   7.     A unit dosage form in accordance with claim 5 further comprising  
2 as an active ingredient selenomethionine in an amount ranging from about 0.04 mg to  
3 about 1 mg.

1                   8.     A unit dosage form in accordance with claim 5 further comprising  
2 as active ingredients quercetin in an amount ranging from about 6 mg to about 300 mg  
3 and selenomethionine in an amount ranging from about 0.05 mg to about 1 mg.

1                   9.     A unit dosage form in accordance with claim 2 in which  
2                   (a) said thiol-containing glutathione-increasing agent is  
3 L-2-oxothiazolidine-4-carboxylate in an amount ranging from about 80 mg to  
4 about 4000 mg,  
5                   (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an  
6 amount ranging from about 150 mg to about 5000 mg,  
7                   (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in  
8 an amount ranging from about 75 mg to about 2500 mg, and  
9                   (d) said magnesium is in the form of magnesium ascorbate in an amount  
10 ranging from about 80 mg to about 3300 mg.

1                   10.    A unit dosage form in accordance with claim 2 in which  
2                   (a) said thiol-containing glutathione-increasing agent is N-acetyl-  
3 L-cysteine in an amount ranging from about 80 mg to about 4000 mg,  
4                   (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an  
5 amount ranging from about 150 mg to about 5000 mg,  
6                   (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in  
7 an amount ranging from about 75 mg to about 2500 mg, and  
8                   (d) said magnesium is in the form of magnesium L-acetylcysteinate in an  
9 amount ranging from about 80 mg to about 3300 mg.

1                   11.    A unit dosage form in accordance with claim 2 in which  
2                   (a) said thiol-containing glutathione-increasing agent is N-acetyl-  
3 L-cysteine in an amount ranging from about 80 mg to about 4000 mg,  
4                   (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an  
5 amount ranging from about 150 mg to about 5000 mg,

6 (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in  
7 an amount ranging from about 75 mg to about 2500 mg, and  
8 (d) said magnesium is in the form of magnesium 2,N-thioctylcysteinate in  
9 an amount ranging from about 56 mg to about 2800 mg.

1 12. A unit dosage form in accordance with claim 2 in which  
2 (a) said thiol-containing glutathione-increasing agent is N-acetyl-  
3 L-cysteine in an amount ranging from about 80 mg to about 4000 mg,  
4 (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an  
5 amount ranging from about 150 mg to about 5000 mg,  
6 (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in  
7 an amount ranging from about 75 mg to about 2500 mg, and  
8 (d) said magnesium is in the form of magnesium 2,N-thioctyltaurate in an  
9 amount ranging from about 50 mg to about 2500 mg.

1 13. A unit dosage form in accordance with claim 2 in which  
2 (a) said thiol-containing glutathione-increasing agent is N-acetyl-  
3 L-cysteine in an amount ranging from about 80 mg to about 4000 mg,  
4 (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an  
5 amount ranging from about 150 mg to about 5000 mg,  
6 (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in  
7 an amount ranging from about 75 mg to about 2500 mg, and  
8 (d) said magnesium is in the form of magnesium taurate in an amount  
9 ranging from about 80 mg to about 3400 mg.

1 14. A unit dosage form in accordance with claim 2 in which  
2 (a) said thiol-containing glutathione-increasing agent is N-acetyl-  
3 L-cysteine in an amount ranging from about 80 mg to about 4000 mg,  
4 (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an  
5 amount ranging from about 150 mg to about 5000 mg,  
6 (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in  
7 an amount ranging from about 75 mg to about 2500 mg, and  
8 (d) said magnesium is in the form of magnesium acetate in an amount  
9 ranging from about 175 mg to about 5800 mg.

1                   15.     A unit dosage form in accordance with claim 2 in which  
2                   (a) said thiol-containing glutathione-increasing agent is N-acetyl-  
3                   L-cysteine in an amount ranging from about 80 mg to about 4000 mg,  
4                   (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an  
5                   amount ranging from about 150 mg to about 5000 mg,  
6                   (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in  
7                   an amount ranging from about 75 mg to about 2500 mg, and  
8                   (d) said magnesium is in the form of magnesium citrate in an amount  
9                   ranging from about 32 mg to about 1610 mg.

1                   16.     A unit dosage form in accordance with claim 2 in which  
2                   (a) said thiol-containing glutathione-increasing agent is N-acetyl-  
3                   L-cysteine in an amount ranging from about 80 mg to about 4000 mg,  
4                   (b) said L-lysine-increasing agent is L-lysine monohydrochloride in an  
5                   amount ranging from about 150 mg to about 5000 mg,  
6                   (c) said glucosamine-increasing agent is 2-amino-2-deoxy-D-glucose in  
7                   an amount ranging from about 75 mg to about 2500 mg, and  
8                   (d) said magnesium is in the form of magnesium oxide in an amount  
9                   ranging from about 50 mg to about 1600 mg.

1                   17.     A unit dosage form in accordance with claim 5 further comprising  
2                   as an active ingredient zinc picolinate present in an amount ranging from about 7.1 mg to  
3                   about 380 mg.

1                   18.     A unit dosage form in accordance with claim 5 further comprising  
2                   as an active ingredient copper sulfate present in an amount ranging from about 0.40 mg to  
3                   about 14 mg.

1                   19.     A unit dosage form in accordance with claim 5 further comprising  
2                   as active ingredients zinc picolinate in an amount ranging from about 7.1 mg to about 380  
3                   mg and copper sulfate in an amount ranging from about 0.40 mg to about 14 mg.

1                   20.     A unit dosage form in accordance with claim 17 in which said zinc  
2                   is in the form of zinc sulfate and is present in an amount ranging from about 3.7 mg to  
3                   about 198 mg.

1                   21.     A unit dosage form in accordance with claim 17 in which said zinc  
2 is in the form of zinc dinicotinate and is present in an amount ranging from about 7.1 mg  
3 to about 380 mg.

1                   22.     A unit dosage form in accordance with claim 17 in which said zinc  
2 is in the form of zinc ascorbate and is present in an amount ranging from about 9.5 mg to  
3 about 500 mg.

1                   23.     A unit dosage form in accordance with claim 17 in which said zinc  
2 is in the form of zinc L-acetylcysteinate and is present in an amount ranging from about 9  
3 mg to about 480 mg.

1                   24.     A unit dosage form in accordance with claim 17 in which said zinc  
2 is in the form of zinc L-lysinate and is present in an amount ranging from about 8 mg to  
3 about 435 mg.

1                   25.     A unit dosage form in accordance with claim 18 in which said unit  
2 dosage form is an oral dosage form and said  $\text{Cu}^{+2}$  is in the form of copper  
3 L-acetylcysteinate and is present in an amount ranging from about 1 mg to about 30 mg.

1                   26.     A unit dosage form in accordance with claim 8 further comprising  
2 as an active ingredient zinc picolinate in an amount ranging from about 7.1 mg to about  
3 380 mg.

1                   27.     A unit dosage form in accordance with claim 8 further comprising  
2 as an active ingredient copper sulfate in an amount ranging from about 0.40 mg to about  
3 14.0 mg.

1                   28.     A unit dosage form in accordance with claim 8 further comprising  
2 as an active ingredient zinc picolinate in an amount ranging from about 7.1 mg to about  
3 380 mg and copper sulfate in an amount ranging from about 0.40 mg to about 14.0 mg.

1                   29.     A layered tablet for the treatment of herpes simplex and conditions  
2 giving rise thereto, said layered tablet comprising an immediate-release layer and a  
3 sustained-release layer, and comprising the following as active ingredients distributed

4 between said immediate-release layer and said sustained-release layer in the following  
5 approximate proportions expressed as relative weight percents:

	<u>Immediate-Release Layer</u>	<u>Sustained-Release Layer</u>
Magnesium L-ascorbate	40-60%	balance
2-Amino-2-deoxy-D-glucose	40-60%	balance
L-lysine monohydrochloride	40-60%	balance
N-acetyl-L-cysteine	40-60%	balance
Quercetin	40-60%	balance
L-Selenomethionine	100%	
Copper sulfate	100%	
Zinc picolinate	40-60%	balance

1 30. A layered tablet for use as an oral dosage form, said layered tablet  
2 comprising an immediate-release layer and a sustained-release layer, and comprising the  
3 following as active ingredients distributed between said immediate-release layer and said  
4 sustained-release layer in the following approximate proportions expressed as relative  
5 weight percents:

	<u>Immediate-Release Layer</u>	<u>Sustained-Release Layer</u>
Magnesium taurate	40-60%	balance
L-selenomethionine	100%	
2-Amino-2-deoxy-D-glucose	40-60%	balance
L-Lysine ascorbate	50-60%	balance
Copper sulfate	100%	
Zinc lysinate	40-60%	balance
N-acetyl-L-cysteine	40-60%	balance
Quercetin	40-60%	balance

1 31. A unit dosage form for the treatment of herpes simplex and  
2 conditions giving rise thereto, said unit dosage form comprising as active ingredients:

3 (a) a thiol-containing glutathione-increasing agent having the formula

4 RMX

5 in which:

6 R is a member selected from the group consisting of N-acetyl-  
7 L-cysteine, L-2-oxothiazolidine-4-carboxylate,  
8 N-2(-mercaptopropionyl)-glycine, and L-lysine,  
9 M is a member selected from the group consisting of  $Mg^{+2}$ ,  $Cu^{+2}$ ,  
10  $Zn^{+2}$ , and  $Se^{+2}$ , and  
11 X is a member selected from the group consisting of hydroxide,  
12 halide, sulfate, acetate, ascorbate, and bis-ascorbate;  
13 (b) an L-lysine-increasing agent,  
14 (c) a glucosamine-increasing agent, and  
15 (d) magnesium.

1 32. A unit dosage form for the treatment of herpes simplex and  
2 conditions giving rise thereto, said unit dosage form comprising as active ingredients:

3 (a) a thiol-containing glutathione-increasing agent having the formula  
4  $RMg^{+2}X$

5 in which:

6 R is a member selected from the group consisting of cysteine,  
7 N-acetyl-L-cysteine, L-2-oxothiazolidine-4-carboxylate,  
8 N-2(-mercaptopropionyl)-glycine, and L-lysine, and

9 X is a member selected from the group consisting of hydroxide,  
10 halide, sulfate, phosphate, acetate, ascorbate, and bis-  
11 ascorbate;

12 (b) an L-lysine-increasing agent,  
13 (c) a glucosamine-increasing agent, and  
14 (d) magnesium.

1 33. A unit dosage form for the treatment of herpes simplex and  
2 conditions giving rise thereto, said unit dosage form comprising as active ingredients:

3 (a) a thiol-containing glutathione-increasing agent having the formula  
4  $RCu^{+2}X$

5 in which:

6 R is a member selected from the group consisting of cysteine,  
7 acetylcysteine, N-acetyl-cysteine, L-2-oxothiazolidine-

8 4-carboxylate, N-2(-mercaptopropionyl)-glycine, and  
9 L-lysine, and  
10 X is a member selected from the group consisting of hydroxide,  
11 halide, sulfate, phosphate, and acetate;  
12 (b) an L-lysine-increasing agent,  
13 (c) a glucosamine-increasing agent, and  
14 (d) magnesium.

1 34. A unit dosage form for the treatment of herpes simplex and  
2 conditions giving rise thereto, said unit dosage form comprising as active ingredients:

- 3 (a) a thiol-containing glutathione-increasing agent;  
4 (b) an L-lysine-increasing agent,  
5 (c) a glucosamine-increasing agent,  
6 (d) magnesium, and  
7 (e) a complex having the formula



9 in which:

10 R is a member selected from the group consisting of cysteine,  
11 acetylcysteine, N-acetyl-cysteine, L-2-oxothiazolidine-  
12 4-carboxylate, N-2(-mercaptopropionyl)-glycine, and  
13 L-lysine, and

14 X is a member selected from the group consisting of hydroxide,  
15 halide, sulfate, phosphate, acetate, ascorbate, and bis-  
16 ascorbate.

1 35. A unit dosage form for the treatment of herpes simplex and  
2 conditions giving rise thereto, said unit dosage form comprising as active ingredients:

- 3 (a) a thiol-containing glutathione-increasing agent;  
4 (b) an L-lysine-increasing agent,  
5 (c) a glucosamine-increasing agent,  
6 (d) magnesium,  
7 (e) copper,  
8 (f) zinc, and  
9 (g) selenium,



10 at least one of (d), (e), (f), and (g) being in the form of a complex having the formula

11 
$$R_nMX$$

12 in which:

13 R is a member selected from the group consisting of

14 2,N-thioctylcysteine, 2,N-thioctyllysine, and

15 2,N-thioctyltaurine,

16 n is 1 or 2,

17 M is a member selected from the group consisting of  $Mg^{+2}$ ,  $Cu^{+2}$ ,

18  $Zn^{+2}$ , and  $Se^{+2}$ , and

19 X is a member selected from the group consisting of hydroxide,

20 halide, sulfate, acetate, ascorbate, and bis-ascorbate.

1 36. A unit dosage form for the treatment of herpes simplex and  
2 conditions giving rise thereto, said unit dosage form being an ophthalmic eyedrop dosage  
3 form comprising as active ingredients:

4 (a) ascorbic acid,

5 (b) 2-amino-2-deoxy-D-glucose,

6 (c) zinc sulfate, and

7 (d) L-lysine hydrochloride.

1 37. A unit dosage form in accordance with claim 36 in which the  
2 concentrations of said active ingredients are as follows:

3 (a) about 1.3  $\mu\text{g/mL}$  to about 30  $\mu\text{g/mL}$  of ascorbic acid,

4 (b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-  
5 glucose,

6 (c) about 0.06  $\mu\text{g/mL}$  to about 8.5  $\mu\text{g/mL}$  of zinc sulfate, and

7 (d) about 1.6  $\mu\text{g/mL}$  to about 23  $\mu\text{g/mL}$  of L-lysine hydrochloride.

1 38. A unit dosage form in accordance with claim 37 further comprising  
2 as an active ingredient copper sulfate in a concentration ranging from about 0.4  $\mu\text{g/mL}$  to  
3 about 15  $\mu\text{g/mL}$ .

1 39. A unit dosage form in accordance with claim 37 further comprising  
2 as an active ingredient heparin sodium in a concentration ranging from about 0.6  
3 units/mL to about 8 units/mL.

1                   40.     A unit dosage form in accordance with claim 37 further comprising  
2 as active ingredients copper sulfate in a concentration ranging from about 0.4 µg/mL to  
3 about 15 µg/mL and heparin sodium in a concentration ranging from about 0.6 units/mL  
4 to about 8 units/mL.

1                   41.     A unit dosage form in accordance with claim 37 further comprising  
2 as an active ingredient N-acetyl-L-cysteine in a concentration ranging from about 0.02  
3 mg/mL to about 0.5 mg/mL.

1                   42.     A unit dosage form in accordance with claim 37 further comprising  
2 as an active ingredient L-2-oxothiazolidine-4-carboxylate in a concentration ranging from  
3 about 0.02 mg/mL to about 0.5 mg/mL.

1                   43.     A unit dosage form for the treatment of herpes simplex and  
2 conditions giving rise thereto, said unit dosage form being an ophthalmic ointment or gel  
3 comprising as active ingredients:

- 4                   (a) about 1.3 µg/mL to about 30 µg/mL of ascorbic acid,  
5                   (b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-  
6                   glucose,  
7                   (c) about 0.06 µg/mL to about 8.5 µg/mL of zinc sulfate, and  
8                   (d) about 1.6 µg/mL to about 23 µg/mL of L-lysine hydrochloride.

1                   44.     A unit dosage form in accordance with claim 43 further comprising  
2 as an active ingredient copper sulfate in a concentration ranging from about 0.4 µg/mL to  
3 about 15 µg/mL.

1                   45.     A unit dosage form in accordance with claim 43 further comprising  
2 as an active ingredient quercetin in a concentration ranging from about 0.12 µg/mL to  
3 about 2.75 µg/mL.

1                   46.     A unit dosage form in accordance with claim 43 further comprising  
2 as an active ingredient heparin sodium in a concentration ranging from about 0.6  
3 units/mL to about 8 units/mL.

1                   47.     A unit dosage form in accordance with claim 43 further comprising  
2 as active ingredients quercetin in a concentration ranging from about 0.12 µg/mL to about

3 2.75 µg/mL and heparin sodium in a concentration ranging from about 0.6 units/mL to  
4 about 8 units/mL.

1 48. A unit dosage form in accordance with claim 43 further comprising  
2 as active ingredients quercetin in a concentration ranging from about 0.12 µg/mL to about  
3 2.75 µg/mL, heparin sodium in a concentration ranging from about 0.6 units/mL to about  
4 8 units/mL, and N-acetyl-L-cysteine in a concentration ranging from about 0.02 mg/mL  
5 to about 0.5 mg/mL.

1 49. A unit dosage form for the treatment of herpes simplex and  
2 conditions giving rise thereto, said unit dosage form being a vaginal dosage form selected  
3 from the group consisting of vaginally appropriate suppositories, creams, tablets and gels,  
4 comprising as active ingredients:

- 5 (a) about 1.3 µg/mL to about 30 µg/mL of ascorbic acid,  
6 (b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-  
7 glucose,  
8 (c) about 0.06 µg/mL to about 8.5 µg/mL of zinc sulfate, and  
9 (d) about 1.6 µg/mL to about 23 µg/mL of L-lysine hydrochloride.

1 50. A unit dosage form in accordance with claim 49 further comprising  
2 as an active ingredient copper sulfate in a concentration ranging from about 0.4 µg/mL to  
3 about 15 µg/mL.

1 51. A unit dosage form in accordance with claim 49 further comprising  
2 as an active ingredient quercetin in a concentration ranging from about 0.12 µg/mL to  
3 about 2.75 µg/mL.

1 52. A unit dosage form in accordance with claim 49 further comprising  
2 as an active ingredient heparin sodium in a concentration ranging from about 0.6 unit/mL  
3 to about 8 units/mL.

1 53. A unit dosage form in accordance with claim 49 further comprising  
2 as an active ingredient quercetin in a concentration ranging from about 0.12 µg/mL to  
3 about 2.75 µg/mL and heparin sodium in a concentration ranging from about 0.6 unit/mL  
4 to about 8 units/mL.

1                   54.     A unit dosage form in accordance with claim 49 further comprising  
2     as an active ingredient quercetin in a concentration ranging from about 0.12 µg/mL to  
3     about 2.75 µg/mL, heparin sodium in a concentration ranging from about 0.6 unit/mL to  
4     about 8 units/mL, and N-acetylcysteine in a concentration ranging from about 0.6  
5     units/mL to about 8 units/mL.

1                   55.     A unit dosage form for the treatment of herpes simplex and  
2     conditions giving rise thereto, said unit dosage form being a mucosal dosage form  
3     selected from the group consisting of vaginally appropriate suppositories, creams, tablets  
4     and gels, comprising as active ingredients:

- 5                   (a) ascorbic acid,  
6                   (b) 2-amino-2-deoxy-D-glucose,  
7                   (c) zinc sulfate, and  
8                   (d) L-lysine hydrochloride.

1                   56.     A unit dosage form in accordance with claim 55 in which the  
2     concentrations of said active ingredients are as follows:

- 3                   (a) about 1.3 µg/mL to about 30 µg/mL of ascorbic acid,  
4                   (b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-  
5                   glucose,  
6                   (c) about 0.06 µg/mL to about 8.5 µg/mL of zinc sulfate, and  
7                   (d) about 1.6 µg/mL to about 23 µg/mL of L-lysine hydrochloride.

1                   57.     A unit dosage form in accordance with claim 55 further comprising  
2     as an active ingredient copper sulfate in a concentration ranging from about 0.4 µg/mL to  
3     about 15 µg/mL.

1                   58.     A unit dosage form in accordance with claim 55 further comprising  
2     as an active ingredient heparin sodium in a concentration ranging from about 0.6  
3     units/mL to about 8 units/mL.

1                   59.     A unit dosage form in accordance with claim 55 further comprising  
2     as active ingredients copper sulfate in a concentration ranging from about 0.4 µg/mL to  
3     about 15 µg/mL and heparin sodium in a concentration ranging from about 0.6 units/mL  
4     to about 8 units/mL.

1                   60.    A unit dosage form in accordance with claim 55 further comprising  
2 as an active ingredient N-acetyl-L-cysteine in a concentration ranging from about 0.02  
3 mg/mL to about 0.5 mg/mL.

1                   61.    A unit dosage form in accordance with claim 55 further comprising  
2 as an active ingredient L-2-oxothiazolidine-4-carboxylate in a concentration ranging from  
3 about 0.02 mg/mL to about 0.5 mg/mL.

1                   62.    A unit dosage form for the treatment of herpes simplex and  
2 conditions giving rise thereto, said unit dosage form being a topical dermal dosage form  
3 selected from the group consisting of topical lotions, gels, creams, and emulsions,  
4 comprising as active ingredients:

- 5                   (a) ascorbic acid,  
6                   (b) 2-amino-2-deoxy-D-glucose,  
7                   (c) zinc sulfate, and  
8                   (d) L-lysine hydrochloride.

1                   63.    A unit dosage form in accordance with claim 62 in which the  
2 concentrations of said active ingredients are as follows:

- 3                   (a) about 1.3 µg/mL to about 30 µg/mL of ascorbic acid,  
4                   (b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-  
5                   glucose,  
6                   (c) about 0.06 µg/mL to about 8.5 µg/mL of zinc sulfate, and  
7                   (d) about 1.6 µg/mL to about 23 µg/mL of L-lysine hydrochloride.

1                   64.    A unit dosage form in accordance with claim 63 further comprising  
2 as an active ingredient  $\text{Cu}^{+2}$  in a concentration ranging from about 0.15 µg/mL to about  
3 15 µg/mL.

1                   65.    A unit dosage form in accordance with claim 64 further comprising  
2 as an active ingredient quercetin in a concentration ranging from about 0.12 µg/mL to  
3 about 2.75 µg/mL.

1                    66.     A unit dosage form in accordance with claim 65 further comprising  
2 as an active ingredient heparin sodium in a concentration ranging from about 0.6 unit/mL  
3 to about 8 units/mL.

1                    67.     A unit dosage form in accordance with claim 66 further comprising  
2 as an active ingredient D, $\alpha$ -tocopherol in a concentration ranging from about 16  $\mu$ g/mL to  
3 about 1600  $\mu$ g/mL.

1                    68.     A unit dosage form in accordance with claim 67 in which said D, $\alpha$ -  
2 tocopherol is in the form of D, $\alpha$ -tocopherol nicotinate in a concentration ranging from  
3 about 19  $\mu$ g/mL to about 2600  $\mu$ g/mL.

1                    69.     A unit dosage form in accordance with claim 67 in which said D, $\alpha$ -  
2 tocopherol is in the form of D, $\alpha$ -tocopherol succinate in a concentration ranging from  
3 about 19  $\mu$ g/mL to about 2500  $\mu$ g/mL.